Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Olivia F. Duffield, BS
Advertisement
Duffield is a third-year medical student at the Lewis Katz School of Medicine at Temple University in Philadelphia, Pennsylvania.
Articles by Olivia F. Duffield, BS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Developing a COVID-19 Vaccine Alternative
2
Real-World Data Reinforce Effectiveness and Safety of Fecal Microbiota Therapy for Preventing Recurrent C difficile
3
Practically Expanding AI's role in Infectious Diseases
4
Maternal and Infant RSV Immunization Safe, Boosts Antibody Levels Regardless of Sequence
5
